Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
EAST RUTHERFORD, N.J., Nov. 01, 2016 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that third quarter 2016 financial results will be released on Friday, November 4, 2016 before the market opens.
The Company will host a conference call to discuss the financial results.
| Third Quarter 2016 Earnings Conference Call | ||
| When: | Friday, November 4, 2016 at 8:30 a.m. Eastern Time | |
| Dial-in: | 1-888-262-8770 for U.S. | |
| 1-913-312-1227 for International | ||
| Passcode: 2914880 | ||
| Dial-in Replay: | 1-888-203-1112 for U.S. | |
| 1-719-457-0820 for International | ||
| Passcode: 2914880 | ||
| Available through Friday, November 11, 2016 | ||
| Webcast: | www.cambrex.com | |
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura Investor Relations Associate Tel: 201-804-3037 Email: [email protected]
